Does the treatment of maternal Attention Deficit Hyperactivity Disorder enhance the effectiveness of parent management training for children's attention deficit hyperactivity disorder?
ISRCTN | ISRCTN73911400 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN73911400 |
Secondary identifying numbers | BMBF-ADHD-C2 |
- Submission date
- 20/10/2006
- Registration date
- 29/03/2007
- Last edited
- 17/12/2018
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Andreas Warnke
Scientific
Scientific
Department of Child and Adolescent Psychiatry and Psychotherapy
Wuerzburg University Hospital
Fuechsleinstr. 15
Wuerzburg
D-97080
Germany
Phone | +49 (0)931 780 10 |
---|---|
warnke@kjp.uni-weurzburg.de |
Study information
Study design | Randomised controlled trial, open study design, observer blinded |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Other |
Study type | Treatment |
Scientific title | Does the treatment of maternal Attention Deficit Hyperactivity Disorder enhance the effectiveness of parent management training for children's attention deficit hyperactivity disorder? |
Study acronym | AIMAC: (ADHD In Mothers And Children) |
Study objectives | Attention Deficit Hyperactivity Disorder (ADHD) is a serious mental disorder with a persistent pattern of severely impaired attention and concentration, hyperactive and impulsive behaviour, emotional instability, restlessness and disorganised behaviour. The prevalence in childhood is estimated to be about 5% and in adulthood the prevalence is indicated to 2% and 4%. ADHD is highly familial. About one quarter of children presenting with ADHD will have an ADHD parent, and more than half of all parents with ADHD will have a child with ADHD. Bringing up a child with ADHD can prove to be very stressful. Calm and consistent parenting in structured settings is especially important. However, parents with ADHD are less likely to be able to provide such care. Parent's ADHD can be expected to have negative impact on parenting, family functioning, and the child. Parental ADHD may also have negative influence on the treatment outcome of childhood ADHD. This may especially be the case for the efficacy of parent management training, because parents with ADHD are expected to present difficulties in following instructions and in complying with the treatment regime. Furthermore they tend to impulsively switch to alternative treatment plans promising quick cures, to act disorganised and argumentative or to have problems with the implementation of token economies and consistent rewards. Therefore, the control of ADHD symptoms in parents is supposed to be a prerequisite for the success of parenting programs for ADHD children. The proposed study will be the first controlled multi-centre clinical trial investigating the effect of the treatment of maternal ADHD on the efficacy of parent management training for childhood ADHD. The principal research question is: Does the treatment of maternal ADHD enhance the effectiveness of parent management training for children's ADHD? Other questions to be addressed are: 1. To what extent does treatment effects generalise across problem areas (ADHD core-symptoms, externalising symptoms at home, family functioning, global symptom severity), settings (school and home environment) and rater-perspectives respectively (child, mother, teacher)? 2. Is there a greater acceptance of parent management training in mothers treated for ADHD? 3. Are the effects of treatment stable over time? 4. Does the sole treatment of maternal ADHD already have influences on the childs symptoms? 5. Is there an association between the child's co-morbidity and treatment outcome? The main hypothesis is: parent management training for children's ADHD is more effective in children whose mothers received treatment for adult ADHD as in children whose mothers did not. |
Ethics approval(s) | Ethics Committee of the faculty of medicine, Wuerzburg University, ref: 120/06 |
Health condition(s) or problem(s) studied | Attention Deficit Hyperactivity Disorder (ADHD) in children and their mothers |
Intervention | Two-armed design: Experimental Group (EG): treatment of mother's ADHD with methylphenidate and a specific group psychotherapy program (12 weekly sessions, followed by monthly sessions, duration: 52 weeks) Control Group (CG): clinical management for mother's ADHD without any specific pharmacological or psychotherapeutic interventions (12 weekly sessions, followed by monthly sessions, duration: 52 weeks) In both groups - after week 13 - children and their mothers will receive parent management training to treat the child's ADHD (12 weekly sessions and two booster sessions). Manualised cognitive-behavioural programs are used for group psychotherapy (ADHD mother) and parent management training (ADHD child). Trained therapists are treating mothers and children. Treatment integrity is ascertained by independent supervision. |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Not Applicable |
Drug / device / biological / vaccine name(s) | Methylphenidate |
Primary outcome measure | Primary endpoint is the extent of externalising symptoms in the children: 1. ADHD-ODD-Scale (ODD: Oppositional Defiant Disorder): number of symptoms of ADHD and ODD present during the last two weeks before assessment (ADHD-section and ODD-section of the Kiddie Schedule for Affective Disorders and Schizophrenia [KIDDIE-SADS], blind investigator-rating) |
Secondary outcome measures | Children: 1. ADHD-section and ODD-section of the KIDDIE-SADS (diagnosis +/-, responders-nonresponders: 30 percent reduction of the ADHD-ODD-Scale, blind investigator-rating) 2. Externalising and internalising symptoms: Strength and Difficulties Questionnaire (SDQ) (mother and teacher report) 3. Family functioning: Home-Situations-Questionnaire (HSQ, mother-report) 4. Impact of the child's symptoms on the family: Family Impact Questionnaire (FIQ, mother-report) 5. Process-quality, related to parent training (Fragebogen zur Beurteilung der Behandlung, FBB, mother- and therapist-report) Mothers: 1. Symptom-Checklist (SCL-90-R, self-rating mother) 2. Conners Adult ADHD Rating Scale (CAARS-S:L, self-rating mother; CAARS-O:L, blind investigator rating) |
Overall study start date | 01/01/2007 |
Completion date | 31/12/2009 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Mixed |
Sex | Both |
Target number of participants | To be randomised: 144 mother-child pairs |
Key inclusion criteria | All patients: 1. Voluntary and written informed consent of the mother, the child and other persons having the care and custody of the child Children: 1. Aged six to 12 years 2. Diagnosis of ADHD according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria 3. No medication or on stable medication for at least four weeks before baseline assessment Mothers: 1. Diagnosis of ADHD according to DSM-IV criteria 2. A score of 30 or more on the short version of the Wender-Utah-Rating-Scale 3. Aged 18 to 60 years, inclusive 4. Chronic course of ADHD symptoms from childhood to adulthood, onset of ADHD symptoms before the age of seven 5. No abnormality detected on physical examination, routine blood testing (blood count, renal, hepatic and thyroid function), Electrocardiogram (ECG) and Electroencephalogram (EEG) |
Key exclusion criteria | All patients: 1. Participation in another clinical trial 2. Specific interventions for the treatment of ADHD within the last six months before screening 3. Need for inpatient treatment Children: 1. Intelligence Quotient (IQ) less than 80 2. Pervasive developmental disorder, psychosis, schizophrenia, bipolar disorder, severe depressive episode Mothers: 1. IQ less than 80 2. Schizophrenia, bipolar disorder, borderline personality disorder, antisocial personality disorder, suicidal or self-injurious behaviour, autism, motor tics, Tourette's syndrome 3. Substance abuse/dependence within six months prior to screening. Episodic abuse is not an exclusion criterion 4. Neurological diseases, seizures, glaucoma, uncontrolled hypertension 5. Current eating disorder/low weight (Body Mass Index [BMI] less than 20) 6. Pregnancy or breast-feeding |
Date of first enrolment | 01/04/2007 |
Date of final enrolment | 01/05/2010 |
Locations
Countries of recruitment
- Germany
Study participating centre
Wuerzburg University Hospital
Wuerzburg
D-97080
Germany
D-97080
Germany
Sponsor information
Wuerzburg University Hospital (Germany)
Hospital/treatment centre
Hospital/treatment centre
Josef-Schneider-Strasse 2
Wuerzburg
D-97080
Germany
Website | http://www-i.klinik.uni-wuerzburg.de/deutsch/Home/content.html |
---|---|
https://ror.org/03pvr2g57 |
Funders
Funder type
Government
Bundesministerium für Bildung und Forschung
Government organisation / National government
Government organisation / National government
- Alternative name(s)
- Federal Ministry of Education and Research, BMBF
- Location
- Germany
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | results | 01/03/2013 | Yes | No | |
Results article | results | 01/12/2015 | Yes | No | |
Results article | results | 13/12/2018 | Yes | No |
Editorial Notes
17/12/2018: Publication reference added.
13/11/2018: The following changes have been made:
1. The recruitment start date has been changed from 01/01/2007 to 01/04/2007.
2. The recruitment end date has been changed from 31/12/2009 to 01/05/2010.